Protagonist Therapeutics (PTGX) Competitors $58.36 -0.02 (-0.03%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. SMMT, RDY, ASND, VTRS, QGEN, BBIO, ROIV, VRNA, ELAN, and MRNAShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen BridgeBio Pharma Roivant Sciences Verona Pharma PLC American Depositary Share Elanco Animal Health Moderna Protagonist Therapeutics (NASDAQ:PTGX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations. Which has stronger valuation & earnings, PTGX or SMMT? Protagonist Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$209.18M17.32$275.19M$0.7083.18Summit Therapeutics$700K19,270.59-$221.32M-$1.01-17.98 Do institutionals and insiders hold more shares of PTGX or SMMT? 98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate PTGX or SMMT? Protagonist Therapeutics currently has a consensus price target of $67.73, suggesting a potential upside of 16.32%. Summit Therapeutics has a consensus price target of $33.79, suggesting a potential upside of 86.05%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09Summit Therapeutics 3 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 Which has more risk & volatility, PTGX or SMMT? Protagonist Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500. Does the media favor PTGX or SMMT? In the previous week, Protagonist Therapeutics had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 30 mentions for Protagonist Therapeutics and 24 mentions for Summit Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.03 beat Summit Therapeutics' score of 1.03 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 7 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is PTGX or SMMT more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Summit Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 8.12% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics24.88% 8.12% 7.41% Summit Therapeutics N/A -208.64%-181.28% SummaryProtagonist Therapeutics beats Summit Therapeutics on 13 of the 17 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.63B$3.10B$5.72B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio83.2521.2575.6826.46Price / Sales17.32383.59493.40165.76Price / Cash13.0344.4425.8129.90Price / Book5.149.6112.836.31Net Income$275.19M-$53.18M$3.29B$270.30M7 Day Performance-0.23%0.50%0.32%2.03%1 Month Performance3.84%4.75%4.71%6.23%1 Year Performance26.03%10.09%68.73%28.08% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics2.291 of 5 stars$58.360.0%$67.73+16.0%+24.2%$3.63B$209.18M83.39120News CoveragePositive NewsAnalyst RevisionSMMTSummit Therapeutics3.3658 of 5 stars$18.94+1.8%$33.79+78.4%-40.7%$14.07BN/A-18.75110Positive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.426 of 5 stars$14.65-0.5%$16.95+15.7%-9.0%$12.23B$3.81B22.2027,811Positive NewsASNDAscendis Pharma A/S3.0157 of 5 stars$195.58-1.1%$244.36+24.9%+63.2%$11.97B$490.75M-37.901,017Positive NewsVTRSViatris1.5918 of 5 stars$9.96-2.1%$10.40+4.4%-17.7%$11.61B$14.74B-3.4332,000QGENQiagen4.4194 of 5 stars$45.30-1.7%$49.69+9.7%+0.7%$10.07B$1.98B26.765,765Positive NewsBBIOBridgeBio Pharma4.4324 of 5 stars$51.21-2.6%$63.94+24.9%+96.6%$9.79B$221.90M-12.52400Analyst ForecastROIVRoivant Sciences2.9366 of 5 stars$14.08-2.3%$17.67+25.5%+16.8%$9.61B$29.05M-20.11860VRNAVerona Pharma PLC American Depositary Share2.2998 of 5 stars$106.43+0.0%$109.00+2.4%+257.2%$9.21B$42.28M-107.5030Positive NewsELANElanco Animal Health2.8161 of 5 stars$18.52-1.4%$17.33-6.4%+28.7%$9.20B$4.44B21.539,000Positive NewsMRNAModerna4.4515 of 5 stars$23.51-7.4%$42.88+82.4%-65.0%$9.15B$3.24B-3.125,800High Trading Volume Related Companies and Tools Related Companies Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Roivant Sciences Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Moderna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored(Please Ignore if Already Rich)Discover how to get access to a weekly livestream with TWO Pro Traders for a full month… And learn their un...Monument Traders Alliance | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTGX Stock Alerts